BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12663664)

  • 61. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation.
    Lee SE; Woo KM; Kim SY; Kim HM; Kwack K; Lee ZH; Kim HH
    Bone; 2002 Jan; 30(1):71-7. PubMed ID: 11792567
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
    Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
    BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
    [TBL] [Abstract][Full Text] [Related]  

  • 63. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
    Kanazawa K; Kudo A
    J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency.
    Kanematsu M; Sato T; Takai H; Watanabe K; Ikeda K; Yamada Y
    J Bone Miner Res; 2000 Jul; 15(7):1321-9. PubMed ID: 10893680
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Osteoclast differentiation by RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6).
    Ogasawara T; Katagiri M; Yamamoto A; Hoshi K; Takato T; Nakamura K; Tanaka S; Okayama H; Kawaguchi H
    J Bone Miner Res; 2004 Jul; 19(7):1128-36. PubMed ID: 15176996
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.
    Takayanagi H; Kim S; Koga T; Nishina H; Isshiki M; Yoshida H; Saiura A; Isobe M; Yokochi T; Inoue J; Wagner EF; Mak TW; Kodama T; Taniguchi T
    Dev Cell; 2002 Dec; 3(6):889-901. PubMed ID: 12479813
    [TBL] [Abstract][Full Text] [Related]  

  • 67. In vitro and in silico analysis of an inhibitory mechanism of osteoclastogenesis by salubrinal and guanabenz.
    Hamamura K; Chen A; Tanjung N; Takigawa S; Sudo A; Yokota H
    Cell Signal; 2015 Feb; 27(2):353-62. PubMed ID: 25435425
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mechanisms involved in enhancement of osteoclast formation and function by low molecular weight hyaluronic acid.
    Ariyoshi W; Takahashi T; Kanno T; Ichimiya H; Takano H; Koseki T; Nishihara T
    J Biol Chem; 2005 May; 280(19):18967-72. PubMed ID: 15757905
    [TBL] [Abstract][Full Text] [Related]  

  • 70. High throughput screening identified a substituted imidazole as a novel RANK pathway-selective osteoclastogenesis inhibitor.
    Chen T; Knapp AC; Wu Y; Huang J; Lynch JS; Dickson JK; Lawrence RM; Feyen JH; Agler ML
    Assay Drug Dev Technol; 2006 Aug; 4(4):387-96. PubMed ID: 16945012
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dimer formation of receptor activator of nuclear factor kappaB induces incomplete osteoclast formation.
    Iwamoto K; Miyamoto T; Sawatani Y; Hosogane N; Hamaguchi I; Takami M; Nomiyama K; Takagi K; Suda T
    Biochem Biophys Res Commun; 2004 Dec; 325(1):229-34. PubMed ID: 15522223
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Differential effects of mechanical strain on osteoclastogenesis and osteoclast-related gene expression in RAW264.7 cells.
    Xu XY; Guo C; Yan YX; Guo Y; Li RX; Song M; Zhang XZ
    Mol Med Rep; 2012 Aug; 6(2):409-15. PubMed ID: 22580758
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling.
    Mazière C; Louvet L; Gomila C; Kamel S; Massy Z; Mazière JC
    J Cell Physiol; 2009 Dec; 221(3):572-8. PubMed ID: 19725047
    [TBL] [Abstract][Full Text] [Related]  

  • 75. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
    Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
    Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
    [TBL] [Abstract][Full Text] [Related]  

  • 78. c-myc is required for osteoclast differentiation.
    Battaglino R; Kim D; Fu J; Vaage B; Fu XY; Stashenko P
    J Bone Miner Res; 2002 May; 17(5):763-73. PubMed ID: 12009006
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
    Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
    Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
    Swanson C; Lorentzon M; Conaway HH; Lerner UH
    Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.